Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

Company Overview - Abeona Therapeutics Inc. (NASDAQ: ABEO) specializes in developing gene and cell therapies aimed at treating serious genetic disorders [1] - The company utilizes its AIM platform, which employs adeno-associated virus (AAV) vectors for the targeted delivery of genetic material, facilitating the correction of functions across multiple body organs [1] Technology and Innovation - The AIM platform represents a significant technological advancement in the field of gene therapy, allowing for precise targeting and delivery of therapeutic genes [1]